Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 8—August 2022
Research

Increasing and More Commonly Refractory Mycobacterium avium Pulmonary Disease, Toronto, Ontario, Canada

Daan Raats1Comments to Author , Sarah K. Brode, Mahtab Mehrabi, and Theodore K. Marras
Author affiliations: Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada (D. Raats, S.K. Brode, M. Mehrabi, T.K. Marras); West Park Health Care Centre, Toronto (S.K. Brode); University of Toronto, Toronto (S.K. Brode, T.K. Marras)

Main Article

Table 2

NTM disease characteristics of patients with Mycobacterium avium and M. xenopi pulmonary disease, Toronto, Ontario, Canada*

Characteristic M. avium
M. xenopi
Early period,
n = 82
Late period,
n = 138
p value Early period,
n = 24
Late period,
n = 8
p value
Previous NTM treatment†
Same species 10 (12.2) 23 (16.7) 0.47 2 (8.3) 1 (12.5) Referent
Any species 12 (14.6) 27 (19.6) 5 (20.8) 2 (25.0)
History of positive AFB smear
53 (64.6)
112 (81.2)
0.01

13 (54.2)
5 (62.5)
Referent
CT pattern
Nodular-bronchiectatic 60 (73.2) 89 (64.5) 0.33 7 (29.2) 1 (12.5) 0.07
Fibrocavitary 17 (20.7) 34 (24.6) 16 (66.7) 4 (50.0)
Other
5 (6.1)
15 (10.9)


1 (4.2)
3 (37.5)

CT cavitation, any size
33 (40.2)
57 (41.3)
0.89

18 (75.0)
4 (50.0)
0.22
Median time from initial visit to treatment initiation, mo (IQR) 1.5 (–15.3 to 17.5) 0.0 (–5.0 to 9.0) 0.39 0.5 (–8.5 to 17.3) 0.5 (–1.0 to 3.75) 0.91

*Values are no. (%) except as indicated. Bold indicates significance. AFB, acid-fast bacilli; CT, computed tomography; IQR, interquartile range; NTM, nontuberculous mycobacteria. †All except 1 M. avium patient with previous treatment history had a record of a single previous treatment episode; all M. xenopi patients with previous treatment history had a record of a single previous treatment episode. P values compare previous treatment for any species

Main Article

1Current affiliation: Ziekenhuis Oost-Limburg, Genk, Belgium.

Page created: June 14, 2022
Page updated: July 20, 2022
Page reviewed: July 20, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external